Regeneron Pharmaceuticals, Inc. (FRA:RGO)

Germany flag Germany · Delayed Price · Currency is EUR
654.00
-12.80 (-1.92%)
Last updated: Feb 20, 2026, 1:51 PM CET
Market Cap67.91B -7.6%
Revenue (ttm)12.22B +1.0%
Net Income3.84B +2.1%
EPS35.33 +8.2%
Shares Outn/a
PE Ratio17.70
Forward PE16.14
Dividend3.09 (0.47%)
Ex-Dividend DateFeb 20, 2026
Volume10
Average Volume15
Open661.60
Previous Close666.80
Day's Range654.00 - 661.60
52-Week Range420.00 - 701.20
Betan/a
RSI51.24
Earnings DateJan 30, 2026

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]

Industry Pharmaceutical Preparations
Founded 1988
Employees 15,410
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol RGO
Full Company Profile

Financial Performance

In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.

Financial numbers in USD Financial Statements